Xu Xu

ORCID: 0000-0002-8958-5302 · 3 papers in corpus
other 2025
Neutrophil CD64 index: a novel biomarker for risk stratification in acute pancreatitis
Frontiers in immunology ·doi:10.3389/fimmu.2025.1526122

OBJECTIVE: Effective early diagnosis and timely intervention in acute pancreatitis (AP) are essential for improving patient outcomes. This study aims to evaluate the clinical utility of the neutrophil CD64 index (nCD64) in stratifying patie…

nonrandomized-trial 2023
Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study
Advances in therapy ·doi:10.1007/s12325-023-02617-8

INTRODUCTION: Triptorelin is available as 1- and 3-month prolonged-release (PR) formulations; at the time of the study, only the former was approved for central precocious puberty (CPP) in China. This study assessed the efficacy and safety …

lab-animal 2021
Research on Quality Markers of Guizhi Fuling Prescription for Endometriosis Treatment Based on Gray Correlation Analysis Strategy
Frontiers in pharmacology ·doi:10.3389/fphar.2020.588549

Guizhi Fuling prescription (GFP), a prestigious prescription of traditional Chinese medicine (TCM) recorded in "Jingui Yaolue," was composed of five Chinese medicines, including Moutan Cortex, Paeoniae Radix Alba, Persicae Semen, Poria Coco…